Bimekizumab Biosimilar – Anti-IL17A, IL17F mAb – Research Grade

Reference:
Size

,

Brand

Product type

Clonality

Expression system

Description of Bimekizumab Biosimilar - Anti-IL17A/IL17F mAb - Research Grade

Description of Bimekizumab Biosimilar - Anti-IL17A/IL17F mAb - Research Grade

General information on Anti-IL17A[Homo sapiens] (Bimekizumab) Monoclonal Antibody

Bimekizumab has beeninvestigated for the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.

Product nameBimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade
SourceCAS 1418205-77-2
SpeciesHumanized
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsCDP4940
ReferencePX-TA1342
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
SourceCAS 1418205-77-2
Product nameBimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade
SourceCAS 1418205-77-2
SpeciesHumanized
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsCDP4940
ReferencePX-TA1342
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
SourceCAS 1418205-77-2

Reviews

There are no reviews yet.

Be the first to review “Bimekizumab Biosimilar – Anti-IL17A, IL17F mAb – Research Grade”

Your email address will not be published.


Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: